About this trial
This study is to learn how the weight loss drug tirzepatide (Zepbound) changes the way a body handles alcohol. 5 participants aged 21-55 who take Zepbound will be enrolled and can expect to be on study for up to 4 weeks.
Eligibility criteria
Qualifiers
At least 21 years of age, no older than 55 years of age
BMI 30-45 kg/m2
Taking stable dose of prescribed, branded tirzepatide for at least 28 days
Self-reported regular alcohol consumption
Disqualifiers
AUDIT score of >8 requires Study Physician review
Use of compounded GLP-1 RA
History of or current substance use disorder as determined by self-reported responses to the Internalizing, Externalizing, and Substance Use Disorder Screener, Drug Use Disorders Identification Test, Alcohol Use Disorder Identification Test
Pregnancy or lactation (pregnancy test, if needed)
Trial design
Treatments tested in this trial
- Acute Ethanol Dose